Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $300.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s target price would indicate a potential upside of 5.42% from the stock’s current price.

Several other research analysts have also commented on the company. UBS Group raised their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Bank of America raised their price objective on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, Evercore ISI upped their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, June 25th. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $285.62.

Alnylam Pharmaceuticals Trading Up 2.1 %

Shares of ALNY traded up $5.95 during trading hours on Friday, hitting $284.57. The company had a trading volume of 283,782 shares, compared to its average volume of 864,914. The company has a market capitalization of $36.53 billion, a PE ratio of -474.28 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $287.55. The company’s fifty day moving average price is $268.85 and its two-hundred day moving average price is $210.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. During the same period in the previous year, the company posted ($2.21) EPS. The business’s revenue for the quarter was up 107.0% compared to the same quarter last year. Analysts forecast that Alnylam Pharmaceuticals will post -2.73 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the sale, the director now owns 136 shares of the company’s stock, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,398 shares of company stock worth $13,595,460. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after buying an additional 50,366 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares during the last quarter. Capital International Investors raised its stake in shares of Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after buying an additional 64,560 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after buying an additional 214,908 shares during the last quarter. Finally, Bellevue Group AG raised its stake in shares of Alnylam Pharmaceuticals by 3.7% during the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock worth $137,238,000 after buying an additional 32,966 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.